克拉屈滨加入初诊成人急性淋巴细胞白血病强化治疗:HOVON-100试验
这项随机3期研究评估在初诊成人急性淋巴细胞白血病(ALL)的诱导和巩固治疗中加入克拉屈滨(CLO)是否改善结局。340例患者随机分组,中位随访70个月,5年无事件生存率A组50% vs B组(CLO组)53%;≤40岁患者A组58% vs B组65%,>40岁两组均为43%。CR率两组均为89%,巩固1后MRD阴性率A组71%(54/76)vs B组93%(75/81)(P=.001),但5年OS相似(60% vs 61%)。CLO组严重不良事件和感染更多、更常退出方案,尤其在老年患者中。结论:尽管MRD阴性率更高,加入CLO并未改善成人ALL结局,可能与毒性增加有关。
要点
- 5年EFS:A组50% vs B组(CLO组)53%,≤40岁A组58% vs B组65%,>40岁两组均为43%。
- 巩固1后MRD阴性率:A组71%(54/76)vs B组93%(75/81),P=.001。
- 5年OS两组相似:A组60% vs B组61%;CLO组严重不良事件和感染更多。
核心结论
- 尽管CLO组MRD阴性率更高,但在初诊成人ALL的诱导和巩固治疗中加入CLO并未改善结局,可能与毒性增加有关。
研究设计与样本
- 随机3期研究,共340例初诊成人ALL患者随机分组。
- 年轻患者(18-40岁)采用儿童样方案,老年患者(41-70岁)采用半强化方案。
主要发现
- 中位随访70个月,5年EFS:A组50% vs B组(CLO组)53%。
- ≤40岁患者5年EFS:A组58% vs B组65%;>40岁患者两组均为43%。
- 两组CR率均为89%,年轻与老年患者相似。
- 巩固1后MRD阴性率:A组71%(54/76)vs B组93%(75/81)(P=.001)。
- 两组均有70例(42%)患者接受异基因造血干细胞移植;5年OS:A组60% vs B组61%。
关键数值与推荐
- 达到CR的患者中,复发率A组28% vs B组24%,CR后非复发死亡率A组16% vs B组17%。
- CLO组严重不良事件更多、感染更多、更常退出方案,在老年患者中最为明显。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clofarabine (CLO) is a nucleoside analog with efficacy in relapsed/refractory acute lymphoblastic leukemia (ALL). This randomized phase 3 study aimed to evaluate whether CLO added to induction and whether consolidation would improve outcome in adults with newly diagnosed ALL. Treatment of younger (18-40 years) patients consisted of a pediatric-inspired protocol, and for older patients (41-70 years), a semi-intensive protocol was used. Three hundred and forty patients were randomized. After a median follow-up of 70 months, 5-year event-free survival (EFS) was 50% and 53% for arm A and B (CLO arm). For patients ≤40 years, EFS was 58% vs 65% in arm A vs B, whereas in patients >40 years, EFS was 43% in both arms. Complete remission (CR) rate was 89% in both arms and similar in younger and older patients. Minimal residual disease (MRD) was assessed in 200 patients (60%). Fifty-four of 76 evaluable patients (71%) were MRD- after consolidation 1 in arm A vs 75/81 (93%) in arm B (P = .001). Seventy (42%) patients proceeded to allogeneic hematopoietic stem cell transplantation in both arms. Five-year overall survival (OS) was similar in both arms: 60% vs 61%. Among patients achieving CR, relapse rates were 28% and 24%, and nonrelapse mortality was 16% vs 17% after CR. CLO-treated patients experienced more serious adverse events, more infections, and more often went off protocol. This was most pronounced in older patients. We conclude that, despite a higher rate of MRD negativity, addition of CLO does not improve outcome in adults with ALL, which might be due to increased toxicity. This trial was registered at www.trialregister.nl as #NTR2004.
引用
- Rijneveld AW, van der Holt B, de Weerdt O, et al. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial. Blood Adv. 2022. PMID: 34883506. doi:10.1182/bloodadvances.2021005624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。